Hengkang Medical's main business scope: healthcare investment management; production, research and development, and sales of pharmaceuticals; sales of daily chemical products and biological products; and the seven hospitals under the umbrella of Hengkang Medical provide diagnosis and treatment services for patients across the country with the core of medical services. At the same time, relying on the big health industry, layout of medicine, daily chemicals, health and other industries. The main products include Duyiwei Capsule, Ginseng Astragalus Wuweizi Tablet, Mai Ping Tablet, Qianlian Pain Tablet, Potassium Chloride Sodium Chloride Injection, Duyiwei Toothpaste, Jizhen Snow Clam, etc. covering pharmaceuticals, daily chemicals and health care products.
1. In September 2001, Sichuan Hengkang Development Co., Ltd. and Gansu Duyiwei Pharmaceutical Co., Ltd.*** jointly invested in the establishment of Gansu Duyiwei Bio-Pharmaceutical Co. In May 2002, the company invested 30 million yuan, in strict accordance with the GMP standard, the design of the new production base with advanced level. Completed and passed the acceptance test in Wangba Duyiwei Industrial Park, Kang County, Gansu Province. It produces 6 dosage forms, 32 varieties, several national new drugs, exclusive varieties of Chinese medicine and protected varieties, and processes 1,500 tons of raw drugs annually. At the same time, the company successfully relocated from Lanzhou to Kang County Duyiwei Biological Industrial Park. The company passed the national GMP certification in one go, and the industrialized production of the company's DuiYiWei softgel capsule was successful, obtaining the new drug production approval. The company's soft capsule production line workshop successfully passed GMP certification, laying the foundation for the large-scale production of new products. The company successfully industrialized Gongliuning capsule, and obtained the new drug production approval.
2, the company's national production of Chinese herbal medicines to support the project "all a flavor of Tibetan medicine artificial planting" success, investment in the construction of Gannan Maqu County, "all a flavor of" grass planting base, covering an area of 30,000 acres, the effect is remarkable. It is of great significance to protect the wild resources of Duyimicao and promote its industrialization. At the same time, the company also applied to the Ministry of Commerce of the People's Republic of China for an exclusive certificate of origin. The Third Extraordinary General Meeting of 2006 of the Company was held in Chengdu. After voting, the overall reorganization plan of the Company was passed. On December 29th, the company was formally restructured into Gansu Duyiwei Bio-Pharmaceutical Co., Ltd. and the first board of directors and supervisory board were produced, and 9 directors and 3 supervisors were elected.
3, the company and the Chinese Medical Association Journal of Continuing Education in Chongqing, Dalian, Beijing, Zibo and other places to organize "medical research thinking and paper writing class", greatly improving the visibility of medical research, the company in Shenzhen small and medium-sized market listing, Gansu Province, the first listed company in the pharmaceutical industry. The company has positioned medical service as its strategic direction, and is fully involved in the medical service industry. The company has made great progress in the field of medical mergers and acquisitions, and has successively acquired 5 hospitals. The company changed its name to Hengkang Medical, strengthened the strategic direction of medical care, began to acquire large-scale second-class hospitals, and actively participated in the restructuring of public hospitals.On the evening of November 12, 2017, Hengkang Medical announced that the company confirmed that the suspension of trading due to a major event was a non-public offering of shares. Among them, the fund-raising investment project involves the acquisition of assets in cash, and the acquisition object is the equity of the medical service industry company, and the transaction amount is expected to be about 3 billion yuan.